AbCellera raises $105M in first major venture round as Covid-19 antibody nears clinic
Over its first decade of existence, AbCellera had many things: A new technology with sci-fi vibes, funding from the Bill & Melinda Gates Foundation, government contracts, partnerships with large pharma companies and biotechs, a research facility in Vancouver with dozens and then eventually over a hundred employees. Even, most recently, a leading experimental Covid-19 treatment.
They just didn’t have what almost every biotech did: streams of venture cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.